Athenex: Athenex appoints chief restructuring officer 'to serve and create value for its stakeholders'
Athenex has named Nick Campbell of Meru LLC its chief restructuring officer as it tries to resolve its financial struggles.
Read full article »
Athenex is a biopharmaceutical company that develops novel immune cell therapies for the treatment of cancer and inflammatory diseases.
Read more